Vancomycin Dosing in Intermittent CVVHDF (5 hours every 48 hours)
For a patient receiving intermittent CVVHDF for 5 hours every 48 hours, start with a loading dose of 20-25 mg/kg (based on actual body weight), followed by maintenance doses of 15-20 mg/kg every 48 hours, timed to be administered after each dialysis session, with mandatory trough monitoring before the next dialysis session to target 15-20 mg/L.
Critical Context: Your Patient Has Intermittent, Not Continuous CRRT
Your scenario describes intermittent renal replacement therapy (5 hours on, then 43 hours off), which is fundamentally different from true continuous CVVHDF. This creates a biphasic pharmacokinetic pattern:
- During dialysis (5 hours): Significant vancomycin clearance occurs
- Between sessions (43 hours): Minimal to no renal clearance, drug accumulation risk
Dosing Algorithm
Loading Dose (First Dose)
- 20-25 mg/kg based on actual body weight 1
- Administer over 1.5-2 hours if dose exceeds 1 gram 2
- Give this dose after the first dialysis session to avoid immediate removal
Maintenance Dosing
- 15-20 mg/kg every 48 hours (synchronized with dialysis schedule)
- Administer immediately after each dialysis session
- This timing prevents drug removal and maximizes the interdialytic interval for therapeutic effect
Rationale for This Approach
The intermittent nature creates unique challenges. Research on continuous CVVHDF shows vancomycin doses of 17.5 mg/kg every 12 hours achieve therapeutic targets 3, but your patient has 43-hour periods without clearance. The FDA labeling for anuria recommends 1000 mg every 7-10 days 1, but your patient has intermittent clearance requiring higher doses.
Key pharmacokinetic considerations:
- Vancomycin half-life extends to 14-18 hours during CVVHDF 3
- Volume of distribution ranges 0.6-1.6 L/kg in dialysis patients 3
- Dialysate flow rate and ultrafiltration rate significantly affect clearance 4
Mandatory Monitoring Strategy
Trough concentration before each dialysis session (every 48 hours):
- Target: 15-20 mg/L for serious infections (bacteremia, endocarditis, osteomyelitis, pneumonia) 2
- Draw level immediately before connecting to dialysis
- This pre-dialysis level serves as your trough and guides dose adjustment
Dose Adjustment Based on Troughs
| Pre-Dialysis Trough | Action |
|---|---|
| <10 mg/L | Increase dose by 25-30% |
| 10-15 mg/L | Increase dose by 15-20% |
| 15-20 mg/L | Continue current dose |
| 20-25 mg/L | Decrease dose by 15% |
| >25 mg/L | Hold dose, recheck in 24h, resume at 25% lower dose |
Critical Pitfalls to Avoid
Do NOT use standard renal dosing nomograms - These assume continuous renal function or true continuous dialysis, neither applies here 2
Do NOT dose during the interdialytic period - The 43-hour gap without clearance will cause supratherapeutic levels if you dose mid-cycle
Do NOT rely on calculated creatinine clearance - Your patient's renal function is artificially controlled by intermittent dialysis 1
Do NOT skip trough monitoring - The intermittent nature creates unpredictable pharmacokinetics requiring empiric verification 2, 5
Watch for nephrotoxicity markers - Monitor for ≥2 consecutive serum creatinine increases of 0.5 mg/dL or 150% from baseline, though this is less relevant given existing renal failure 2
Special Considerations
If dialysis schedule changes to 72-hour intervals:
- Increase maintenance dose to 20-25 mg/kg to account for longer interdialytic period
- More frequent subtherapeutic troughs occur with extended intervals 6
If patient has residual urine output:
- 24-hour urine output >500 mL may require dose increase by 10-15% 5
- Weight and urine output independently predict vancomycin levels 5
For obesity (BMI >30):
- Use actual body weight for dosing calculations 2
- May require doses at upper end of range (20-25 mg/kg)
Infusion rate:
- Maximum 10 mg/min to minimize infusion-related reactions 1
- Minimum 60 minutes for any dose, extend to 1.5-2 hours if dose >1 gram 2, 1
Target Therapeutic Endpoints
Your goal is AUC/MIC ≥400 for serious MRSA infections 2, 7. With trough targets of 15-20 mg/L and MIC ≤1 mg/L, this translates to adequate clinical outcomes 2, 7. Pre-dialysis concentrations correlate strongly with AUC (R² = 0.921), making them reliable surrogates 7.